ライフサイエンスコーパス: carbapenem

1 ly to have poor outcomes when treated with a carbapenem.

2 a who all received definitive therapy with a carbapenem.

3 cephalosporin who were subsequently given a carbapenem.

4 use of broad-spectrum antibiotics, including carbapenems.

5 g resistance to the last resort antibiotics, carbapenems.

6 evolved resistance to antibiotics, including carbapenems.

7 lies: penicillin/cephalosporins, clavams and carbapenems.

8 enged with escalating doses of aztreonam and carbapenems.

9 tion or other beta-lactamases that hydrolyze carbapenems.

10 tion to lower susceptibility breakpoints for carbapenems.

11 , including penicillins, cephalosporins, and carbapenems.

12 yses to compare the efficacy of cefepime and carbapenems.

13 e to tolerate quinolones, glycopeptides, and carbapenems.

14 acts specifically with PBP2, and for several carbapenems.

15 ted cross-reactivity between penicillins and carbapenems.

16 are the main mechanism of resistance against carbapenems.

17 ssociated with a worse outcome compared with carbapenems.

18 th such drugs (other active drugs [OADs]) or carbapenems.

19 d because many isolates display low MICs for carbapenems.

20 the best available therapy group received a carbapenem, 161 (96%) as monotherapy.

21 ics were fluoroquinolones (35%), followed by carbapenems (20%), TMP-SMX (18.5%), and ceftazidime (11%

22 tive skin test results to both aztreonam and carbapenems; 211 accepted challenges and tolerated them.

23 d p=0.011), and antibiotic use, particularly carbapenems (45 [9%] vs 18 [24%], adjusted p=0.002) and

24 There was increased consumption of carbapenems (45%) and polymixins (13%), two last-resort

25 Combined with a carbapenem, 9f is a promising product for the treatment

26 ents were excluded if they did not receive a carbapenem after ESBL production was identified.

27 inhibitor, notably restoring the activity of carbapenems against KPC-producing strains.

28 eta-lactamase inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infec

29 Carbapenem and colistin are the last-resort antibiotics

30 baumannii bacteremia, treated with colistin-carbapenem and colistin-tigecycline combinations.

31 s with malignancy, with special attention to carbapenem and expanded-spectrum beta-lactam resistance

32 Of the savings, $54,150 (78%) was related to carbapenems and $15,274 (22%) was due to other antibioti

33 patients were included; 249 received empiric carbapenems and 86 OADs.

34 nce to all the tested antimicrobials, except carbapenems and amikacin, was observed in a proportion o

35 antibiotic treatments, and more recently to carbapenems and colistin, make UTI a prime example of th

36 revious use of beta-lactam/beta-lactamase or carbapenems and recent hospitalization were independent

37 with the highly unstable beta-lactam ring of carbapenems and that the triazole ring generated by this

38 t mortality rate was a combination of CMS, a carbapenem, and ampicillin-sulbactam.

39 A range of specific AMR concerns, including carbapenem- and colistin-resistant gram-negative organis

40 sp. ATCC 39006, intrinsic resistance to the carbapenem antibiotic 1-carbapen-2-em-3-carboxylic acid

41 emonstrating that a combination of AMA and a carbapenem antibiotic has therapeutic potential to addre

42 monitor the hydrolytic decomposition of the carbapenem antibiotic meropenem inside Escherichia coli

43 ve utility, the biosynthesis of the paradigm carbapenem antibiotic, thienamycin, remains largely unkn

44 on increasing concentrations of imipenem, a carbapenem antibiotic.

45 ed with meropenem, a common anti-Pseudomonal carbapenem antibiotic.

46 We investigated 117 isolates resistant to carbapenem antibiotics (either imipenem or meropenem).

47 (MBL) inhibitors can restore the function of carbapenem antibiotics and therefore help to treat infec

48 c beta-lactam/2-pyrrolidine precursor to all carbapenem antibiotics is biosynthesized by attachment o

49 ens the use of penicillin, cephalosporin and carbapenem antibiotics to treat infections.

50 a-lactamase that efficiently hydrolyzes only carbapenem antibiotics.

51 that they are unlikely to mediate passage of carbapenem antibiotics.

52 by crystal violet, osmotic shock, and select carbapenem antibiotics.

53 en implicated in the uptake of ornithine and carbapenem antibiotics.

54 jor porin OprD responsible for the uptake of carbapenem antibiotics.

55 antibiotic use and the use of moxifloxacin, carbapenems, antipseudomonal penicillins, and vancomycin

56 However, carbapenems approved for human use have never been optim

57 Carbapenems are frequently the last line of defence in s

58 erobacteriaceae threaten human health, since carbapenems are last resort drugs for infections by such

59 Carbapenems are recommended for treatment of Enterobacte

60 Several of our new carbapenems are superior to meropenem both with respect

61 Carbapenems are widely regarded as the antibiotics of ch

62 We compared 14-day mortality of PTZ vs carbapenems as empiric therapy in a cohort of patients w

63 CarO (carbapenem-associated outer membrane protein) from Acine

64 iocyanate with meropenem, we have prepared a carbapenem-based fluorescent beta-lactam.

65 Its classification as a carbapenem beta-lactam and the position of its fluoresce

66 The use of non-carbapenem beta-lactams for the treatment of ESBL infect

67 w refinement of the central steps in complex carbapenem biosynthesis.

68 al and Laboratory Standards Institute (CLSI) carbapenem breakpoints for Enterobacteriaceae and the la

69 tibiotics has led to a greater reliance upon carbapenems, but the expression of carbapenemases threat

70 re currently compromising the utility of the carbapenem class of antibacterials.

71 Combinations of beta-lactams of the carbapenem class, such as meropenem, with clavulanate, a

72 ta-lactam and the five-membered rings of the carbapenem core.

73 Cox models determined that every additional carbapenem defined daily dose increased the hazard of ac

74 riaceae highlights the urgent need to reduce carbapenem dependence.

75 ests that the size of susbtituents at C-2 of carbapenem (e.g., benzoic acid of ertapenem) has signifi

76 eived PTZ empirically and 110 (52%) received carbapenems empirically.

77 bability that a patient would receive PTZ vs carbapenems empirically.

78 the efficacy of active alternative drugs to carbapenems except beta-lactam/beta-lactamase inhibitors

79 Metronidazole and carbapenems exhibited reliable activity, although pipera

80 On multivariate analysis, prior carbapenem exposure (OR: 3.23; 95% CI: 1.67-6.25) and he

81 Carbapenem exposure had the strongest association with r

82 Carbapenem exposure quadrupled the hazards of acquiring

83 The cross-reactivity between penicillins and carbapenems for IgE-mediated reactions is very low, but

84 Cefepime has a similar efficacy as carbapenems for the treatment of Enterobacter species ba

85 PTZ appears inferior to carbapenems for the treatment of ESBL bacteremia.

86 s for the detection of intact and hydrolyzed carbapenems from an enrichment broth were developed.

87 n-tigecycline group was 18% and for colistin-carbapenem group was 0% (p=0.059).

88 nsitize resistant Gram-negative pathogens to carbapenems has not been found.

89 han 2 mg/L compared with the use of colistin-carbapenem (hazard ratio, 6.93; 95% CI, 1.61-29.78; p=0.

90 tes may be higher between cephalosporins and carbapenems; however, minimal data are available.

91 eport a biochemical and biophysical study of carbapenem hydrolysis by the B1 enzymes NDM-1 and BcII i

92 in the conferred levels of resistance to the carbapenem imipenem and other beta-lactams.

93 ity (>95%) to amikacin, tigecycline, and the carbapenems (imipenem and meropenem); 90.8% of Acinetoba

94 The permeability of two zwitterionic carbapenems, imipenem and meropenem, measured using lipo

95 stin-tigecycline in 29 patients and colistin-carbapenem in 26.

96 against extended-spectrum cephalosporins and carbapenems in >90% of cases; however, against piperacil

97 enes conferring resistance/susceptibility to carbapenems in Acinetobacter spp. were evaluated.

98 ortality was similar for use of cefepime and carbapenems in adjusted regression models and propensity

99 within the Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRACKLE) was const

100 s, CRACKLE (Consortium on Resistance Against Carbapenems in Klebsiella pneumoniae and Other Enterobac

101 tin and ceftazidime in P. aeruginosa and for carbapenems in Klebsiella species) to 3.0 (for piperacil

102 dime-avibactam as a potential alternative to carbapenems in patients with ceftazidime-resistant Enter

103 dime-avibactam as a potential alternative to carbapenems in patients with nosocomial pneumonia (inclu

104 icate the tolerability of both aztreonam and carbapenems in penicillin-allergic subjects.

105 onephritis), and may offer an alternative to carbapenems in this setting.

106 terobacteriaceae that test as susceptible to carbapenems in vitro for the presence of carbapenemase g

107 e detection of carbapenemase production, the carbapenem inactivation method (CIM), was recently descr

108 ert Carba-R assay, a molecular test, and the carbapenem inactivation method (CIM).

109 se of this study was to develop the modified carbapenem inactivation method (mCIM) for the detection

110 escribe a two-stage evaluation of a modified carbapenem inactivation method (mCIM), in which tryptic

111 on a multicenter evaluation of the modified carbapenem inactivation method (mCIM).

112 NP, the manual Blue Carba, and the modified carbapenem inactivation method for the detection of any

113 ll rapid chromogenic assays and the modified carbapenem inactivation method.

114 This structure of CarG is the first in the carbapenem intrinsic resistance (CIR) family of resistan

115 ty between penicillins or cephalosporins and carbapenems is anticipated as all have a beta lactam rin

116 disease severity (1:1 ratio) to those with a carbapenem MIC of </=1 mg/liter.

117 nts with Enterobacteriaceae infection with a carbapenem MIC of 2 to 8 mg/liter were matched based on

118 ents infected with Enterobacteriaceae with a carbapenem MIC of 2, 4, or 8 mg/liter had higher mortali

119 higher 30-day mortality than the group with carbapenem MICs of </=1 mg/liter (38.9% compared to 5.6%

120 and longer ICU LOS than matched cohorts with carbapenem MICs of </=1 mg/liter, which supports CLSI's

121 The group with carbapenem MICs of 2 to 8 mg/liter had a significantly h

122 am and aminoglycoside combination therapy or carbapenem monotherapy in patients with prior 3GC-R EB c

123 s and any potential use of glycopeptides and carbapenems need to be addressed urgently.

124 stic capacities, who collected the first ten carbapenem non-susceptible clinical isolates of K pneumo

125 Carbapenem nonsusceptibility rates were highest in Acine

126 Cases of CRE were defined as carbapenem-nonsusceptible (excluding ertapenem) and exte

127 erence method (culture and sequencing of any carbapenem-nonsusceptible isolate).

128 isk) and for sequencing of DNA obtained from carbapenem-nonsusceptible isolates for carbapenemase ide

129 nation therapy as use of parenteral colistin-carbapenem or colistin-tigecycline for at least 48 hours

130 rbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of c

131 16 (25%) of those who received single-agent carbapenem (P < .01).

132 Carbapenems, penicillins, and cephalosporins were studie

133 nce (CIR) family of resistance proteins from carbapenem-producing bacteria.

134 ; p = 0.0124) and time-dependent exposure to carbapenems quadrupled the hazard (hazard ratio, 4.087;

135 biotics and more importantly the last resort carbapenems, represent a major mechanism of resistance i

136 s associated with a higher relative risks of carbapenem resistance (CR; P < 0.0001).

137 tablishes that RMDs can discriminate between carbapenem resistance and susceptibility in Acinetobacte

138 As mechanisms of carbapenem resistance are heterogeneous, it is unclear i

139 machine learning classifiers for identifying carbapenem resistance in Acinetobacter baumannii, methic

140 The dissemination of carbapenem resistance in Escherichia coli has major impl

141 particularly KPC, are a common mechanism for carbapenem resistance in this region.

142 Although carbapenem resistance increases the risk of death, the t

143 Carbapenem resistance is a critical healthcare challenge

144 al structure for the Serratia sp. ATCC 39006 carbapenem resistance protein CarG.

145 ae cultures were identified, with an overall carbapenem resistance rate of 24.6%.

146 Carbapenem resistance was mediated primarily by blaKPC-2

147 ses in vitro, major contributors to clinical carbapenem resistance, by removing active site zinc.

148 obacter baumannii are increasingly acquiring carbapenem resistance.

149 useful in tracking other plasmids conferring carbapenem resistance.

150 In the era of carbapenem-resistance in Acinobacter baumannii and Enter

151 Transmissible carbapenem-resistance in Enterobacteriaceae has been rec

152 n sequencing (NGS) revealed that the loss of carbapenem-resistance in KpN06 was due to a 5-kb deletio

153 n of MICs, 49% (n = 98) of the isolates were carbapenem resistant (as defined by either resistance or

154 isolates (n = 26) contained blaKPC and were carbapenem resistant.

155 Carbapenems resistant Enterobacteriaceae infections are

156 y emerging: hypervirulent (hvKP) strains and carbapenem-resistant (CR-KP) strains.

157 nical Acinetobacter isolates and analyzing a carbapenem-resistant A. baumannii (CRAB) outbreak.

158 daily dose increased the hazard of acquiring carbapenem-resistant A. baumannii by 5.1% (hazard ratio,

159 ne, tigecycline, and doxycycline against 107 carbapenem-resistant A. baumannii clinical isolates.

160 ly associated with subsequent development of carbapenem-resistant A. baumannii infections.

161 The primary outcome was the acquisition of carbapenem-resistant A. baumannii on surveillance cultur

162 Presence of carbapenem-resistant A. baumannii on surveillance cultur

163 tients were included, of whom 49 (13.5%) had carbapenem-resistant A. baumannii on surveillance cultur

164 For minocycline susceptibility testing of carbapenem-resistant A. baumannii strains, very major er

165 5% CI, 1.873-8.920; p = 0.0004) of acquiring carbapenem-resistant A. baumannii.

166 0 patients, 45 (12.5%) became colonized with carbapenem-resistant A. baumannii.

167 he formulary, primarily for the treatment of carbapenem-resistant A. baumannii.

168 epidemiology and mechanisms of resistance of carbapenem-resistant Acinetobacter baumannii (CRAB) were

169 Critical-priority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudom

170 Treatment options for infections due to carbapenem-resistant Acinetobacter baumannii are extreme

171 d to determine the effect of the presence of carbapenem-resistant Acinetobacter baumannii in accordan

172 apenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii in the pedi

173 e of colistin methansulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections,

174 The widespread dissemination of carbapenem-resistant Acinetobacter spp. has created sign

175 Analogue 17 was active against carbapenem-resistant and polymyxin-resistant pathogens.

176 er baumannii and Pseudomonas aeruginosa, and carbapenem-resistant and third-generation cephalosporin-

177 e, beta-lactam specificity and metal content.Carbapenem-resistant bacteria pose a major health threat

178 or new therapeutics to combat multidrug- and carbapenem-resistant bacterial pathogens.

179 gs and farmers, providing direct evidence of carbapenem-resistant E. coli transmission and environmen

180 rgence and spread of carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) are a s

181 s to reliably detect carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) is an i

182 he design of fluorogenic probes specific for carbapenem-resistant Enterobacteriaceae (CRE) and they w

183 Carbapenem-resistant Enterobacteriaceae (CRE) are a conc

184 Carbapenem-resistant Enterobacteriaceae (CRE) are a seri

185 Carbapenem-resistant Enterobacteriaceae (CRE) are among

186 Carbapenem-resistant Enterobacteriaceae (CRE) are associ

187 Carbapenem-resistant Enterobacteriaceae (CRE) are emergi

188 Carbapenem-resistant Enterobacteriaceae (CRE) are high-p

189 Carbapenem-resistant Enterobacteriaceae (CRE) are increa

190 we found that the 32-month delay in changing carbapenem-resistant Enterobacteriaceae (CRE) breakpoint

191 Detecting carbapenem-resistant Enterobacteriaceae (CRE) can be dif

192 DC standard methodology for the isolation of carbapenem-resistant Enterobacteriaceae (CRE) from 300 r

193 Since 2010, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) has been i

194 nation ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infreq

195 Carbapenem-resistant Enterobacteriaceae (CRE) have sprea

196 ribing risk factors and clinical outcomes of carbapenem-resistant Enterobacteriaceae (CRE) in sentine

197 Carbapenem-resistant Enterobacteriaceae (CRE) is an emer

198 Two collections of carbapenem-resistant Enterobacteriaceae (CRE) isolates w

199 Carbapenem-resistant Enterobacteriaceae (CRE) producing

200 Carbapenem-resistant Enterobacteriaceae (CRE) spread reg

201 Carbapenem-resistant Enterobacteriaceae (CRE), a group o

202 Here we quantified fecal coliforms (FC), carbapenem-resistant Enterobacteriaceae (CRE), blaNDM-1,

203 Tigecycline MICs among A. baumannii, carbapenem-resistant Enterobacteriaceae (CRE), extended-

204 tervention aimed at containing the spread of carbapenem-resistant Enterobacteriaceae (CRE), primarily

205 Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected p

206 ve against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE).

207 tic resistance and virulence determinants in carbapenem-resistant Enterobacteriaceae and enterohemorr

208 nt for the treatment of infections caused by carbapenem-resistant Enterobacteriaceae and Pseudomonas

209 Carbapenem-resistant Enterobacteriaceae are resistant to

210 Carbapenem-resistant Enterobacteriaceae have recently be

211 The global emergence of carbapenem-resistant Enterobacteriaceae highlights the u

212 In addition, the CREST study (Carbapenem-Resistant Enterobacteriaceae in Solid Organ T

213 Recent outbreaks of carbapenem-resistant Enterobacteriaceae infections assoc

214 Ceftazidime/avibactam is also active against carbapenem-resistant Enterobacteriaceae that produce Kle

215 Carbapenem-resistant Enterobacteriaceae threaten human h

216 domonas aeruginosa, Acinetobacter baumannii, carbapenem-resistant Enterobacteriaceae, and Candida spe

217 inhibitors, multidrug resistant strains and carbapenem-resistant Enterobacteriaceae, and most anaero

218 ms, AmpC beta-lactamase-producing organisms, carbapenem-resistant Enterobacteriaceae, carbapenem-resi

219 Serratia marcescens, a member of the carbapenem-resistant Enterobacteriaceae, is an important

220 re system faced an unprecedented outbreak of carbapenem-resistant Enterobacteriaceae, primarily invol

221 A particularly concerning type of AMR, carbapenem-resistant Enterobacteriaceae, significantly d

222 infection outbreaks, most recently caused by carbapenem-resistant Enterobacteriaceae.

223 Enterobacteriaceae, including 25 isolates of carbapenem-resistant Enterobacteriaceae.

224 ended-spectrum beta-lactamase-producing, and carbapenem-resistant Enterobacteriaceae.

225 in antibiotic-resistance phenotypes against carbapenem-resistant Enterobacteriaceae.

226 overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae.

227 Carbapenem-resistant Enterobacteriacieae (CRE) isolates

228 A carbapenem-resistant Escherichia coli clinical strain WC

229 methicillin-resistant Staphylococcus aureus, carbapenem-resistant Escherichia coli, and extended-spec

230 A total of 96 carbapenem-resistant glucose-nonfermenting isolates were

231 npatients with invasive infections caused by carbapenem-resistant gram-negative bacteria treated with

232 echanisms may underestimate the incidence of carbapenem-resistant gram-negative infections (CRGNIs).

233 The emergence and spread of carbapenem-resistant Gram-negative pathogens is a global

234 a principle contributor to the emergence of carbapenem-resistant Gram-negative pathogens that threat

235 dress the clinical challenge of MBL-positive carbapenem-resistant Gram-negative pathogens.

236 to investigate the predation of an important carbapenem-resistant human pathogen, Klebsiella pneumoni

237 1.3%), including seven from p019-containing, carbapenem-resistant isolates (positive predictive value

238 and D), non-carbapenemase-producing (non-CP) carbapenem-resistant isolates, and carbapenem-susceptibl

239 d detection of potentially blaKPC-containing carbapenem-resistant isolates, providing early and clini

240 We describe an outbreak of carbapenem-resistant K. pneumoniae containing the blaOXA

241 as performed when 9 patients with blaOXA-232 carbapenem-resistant K. pneumoniae infections were ident

242 ately identified 17 patients with blaOxa-232 carbapenem-resistant K. pneumoniae isolates, including 9

243 susceptibility of mice to infection with the carbapenem-resistant K. pneumoniae ST258 strain.

244 nt strains, but limited activity against our carbapenem-resistant K.pneumoniae (12% susceptibility.)

245 Novel therapies are urgently needed to treat carbapenem-resistant Klebsiella pneumoniae (CR-Kp)-media

246 The rapid emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) repres

247 d evaluate an outbreak of OXA-232-expressing carbapenem-resistant Klebsiella pneumoniae (CRKP) transm

248 Despite the growing importance of carbapenem-resistant Klebsiella pneumoniae (CRKP), the c

249 ast-line" treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKp).

250 Carbapenem-resistant Klebsiella pneumoniae infections ar

251 Carbapenem-resistant Klebsiella pneumoniae strains class

252 Carbapenem-resistant Klebsiella pneumoniae strains that

253 ifficile, vancomycin-resistant Enterococcus, carbapenem-resistant Klebsiella pneumoniae, and Escheric

254 Carbapenem-resistant Klebsiella pneumoniae, most notably

255 rk together to determine the risk carried by carbapenem-resistant non-glucose-fermenting Gram-negativ

256 bs from high-risk patients were screened for carbapenem-resistant organisms (CROs) using several meth

257 last 20 years there have been 32 reports of carbapenem-resistant organisms in the hospital water env

258 etrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were tre

259 Carbapenem-resistant Pseudomonas aeruginosa, Acinetobact

260 ms, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa, and carbape

261 Here we tested the hypothesis that carbapenem-resistant ST258 K. pneumoniae is a single gen

262 linical K. pneumoniae strains, including one carbapenem-resistant ST258 strain, are less virulent tha

263 pproach for treatment of infection caused by carbapenem-resistant ST258K.

264 tamase, methicillin-resistant S. aureus, and carbapenem-resistant strains was also observed.

265 Carbapenem-resistant strains were identified based on Cl

266 A total of 360,000 potentially carbapenem-resistant strains were identified from 14.7 m

267 annii (78% susceptibility), including 74% of carbapenem-resistant strains, but limited activity again

268 tients who had received CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii

269 ravenous and/or inhaled CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii

270 r bacterial resistance to cephalosporins and carbapenems, respectively.

271 s (risk ratio, 1.78 [95% CI, 1.24-2.56]) and carbapenems (risk ratio, 2.13 [95% CI, 1.49-3.06]) durin

272 Its use should be further explored as a carbapenem-sparing agent in this clinical scenario.

273 gent underwent skin tests with aztreonam and carbapenems; subjects with negative results were challen

274 t arrest at the acyl-intermediate state with carbapenem substrates but maintain catalytic competency

275 cribe a flow cytometry workflow to determine carbapenem susceptibility from bacterial cell characteri

276 rug resistant and, of 33 isolates tested for carbapenem susceptibility, 12 (36%) were resistant.

277 were prepared by seeding well-characterized carbapenem-susceptible and -nonsusceptible strains into

278 d D carbapenemases, non-CP-CRE isolates, and carbapenem-susceptible isolates were included.

279 (non-CP) carbapenem-resistant isolates, and carbapenem-susceptible isolates.

280 Interestingly, a carbapenem-susceptible K. pneumoniae ST278 (KpN06) was o

281 Carbapenem synthase (CarC), an Fe(II) and 2-(oxo)glutara

282 lude all Enterobacteriaceae resistant to any carbapenem tested.

283 rom the first two steps shared with a simple carbapenem, the pathway sharply diverges to the more str

284 receiving empiric PTZ compared with empiric carbapenem therapy (95% confidence interval, 1.07-3.45).

285 2.5-20.3; P < .001) than those who received carbapenem therapy (n = 161).

286 n greater than 2 mg/L compared with colistin-carbapenem therapy for extensively drug-resistant A. bau

287 high risk of invasive ESBL infections, early carbapenem therapy should be considered.

288 , including penicillins, cephalosporins, and carbapenems, through various mechanisms, resulting in in

289 ble models, there was no association between carbapenem use and persistent bacteremia (adjusted odds

290 However, indiscriminant carbapenem use is not without consequence, and carbapene

291 rd-generation cephalosporin, macrolides, and carbapenem use, exceeding hospital population specific t

292 eiving standard care and were highest during carbapenem use.

293 ate therapy, but could considerably increase carbapenem use.

294 These MbetaLs hydrolyse carbapenems via a similar mechanism, with accumulation o

295 f any type of hypersensitivity reaction to a carbapenem was 3/12 (25%); this included 2 non-IgE-media

296 of suspected hypersensitivity reaction to a carbapenem was 36/838 (4.3%; 95% confidence interval [CI

297 strain G6809 with reduced susceptibility to carbapenems was identified from a patient in a long-term

298 who received empiric treatment with OADs or carbapenems was performed.

299 gecycline versus patients receiving colistin-carbapenem were 35% versus 15% (p=0.105) and 69% versus

300 Amikacin, tigecycline, and the carbapenems were active in vitro against most Gram-negat